Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data

Jesus Gonzalez Bosquet, Douglas C. Marchion, HyeSook Chon, Johnathan M. Lancaster, Stephen Chanock

Research output: Contribution to journalArticle

Abstract

A third of patients with epithelial ovarian cancer (OVCA) will not respond to standard treatment. The determination of a robust signature that predicts chemoresponse could lead to the identification of molecular markers for response as well as possible clinical implementation in the future to identify patients at risk of failing therapy. This pilot study was designed to identify biologic processes affecting candidate pathways associated with chemoresponse and to create a robust gene signature for follow-up studies. After identifying common pathways associated with chemoresponse in serous OVCA in three independent gene-expression experiments, we assessed the biologic processes associated with them using The Cancer Genome Atlas (TCGA) dataset for serous OVCA. We identi fied differential copy-number alterations (CNA), mutations, DNA methylation, and miRNA expression between patients that responded to standard treatment and those who did not or recurred prematurely. We correlated these significant parameters with gene expression to create a signature of 422 genes associated with chemoresponse. A consensus clustering of this signature identified two differentiated clusters with unique molecular patterns: cluster 1 was signi ficant for cellular signaling and immune response (mainly cell-mediated); and cluster 2 was significant for pathways involving DNA-damage repair and replication, cell cycle, and apoptosis. Validation through consensus clustering was performed in five independent OVCA gene-expression experiments. Genes were located in the same cluster with consistent agreement in all five studies (κ coefficient ≥ 0.6 in 4). Integrating high-throughput biologic data have created a robust molecular signature that predicts chemoresponse in OVCA.

Original languageEnglish (US)
Pages (from-to)3902-3912
Number of pages11
JournalCancer Research
Volume74
Issue number14
DOIs
StatePublished - Jul 15 2014
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Gene Expression
Cluster Analysis
Genes
Atlases
Neoplasm Genes
DNA Methylation
MicroRNAs
DNA Replication
Cellular Immunity
DNA Repair
DNA Damage
Cell Cycle
Therapeutics
Genome
Apoptosis
Mutation
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gonzalez Bosquet, J., Marchion, D. C., Chon, H., Lancaster, J. M., & Chanock, S. (2014). Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data. Cancer Research, 74(14), 3902-3912. https://doi.org/10.1158/0008-5472.CAN-14-0186

Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data. / Gonzalez Bosquet, Jesus; Marchion, Douglas C.; Chon, HyeSook; Lancaster, Johnathan M.; Chanock, Stephen.

In: Cancer Research, Vol. 74, No. 14, 15.07.2014, p. 3902-3912.

Research output: Contribution to journalArticle

Gonzalez Bosquet, J, Marchion, DC, Chon, H, Lancaster, JM & Chanock, S 2014, 'Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data', Cancer Research, vol. 74, no. 14, pp. 3902-3912. https://doi.org/10.1158/0008-5472.CAN-14-0186
Gonzalez Bosquet, Jesus ; Marchion, Douglas C. ; Chon, HyeSook ; Lancaster, Johnathan M. ; Chanock, Stephen. / Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data. In: Cancer Research. 2014 ; Vol. 74, No. 14. pp. 3902-3912.
@article{6d1b416e846b4fed8d31482f39e73544,
title = "Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data",
abstract = "A third of patients with epithelial ovarian cancer (OVCA) will not respond to standard treatment. The determination of a robust signature that predicts chemoresponse could lead to the identification of molecular markers for response as well as possible clinical implementation in the future to identify patients at risk of failing therapy. This pilot study was designed to identify biologic processes affecting candidate pathways associated with chemoresponse and to create a robust gene signature for follow-up studies. After identifying common pathways associated with chemoresponse in serous OVCA in three independent gene-expression experiments, we assessed the biologic processes associated with them using The Cancer Genome Atlas (TCGA) dataset for serous OVCA. We identi fied differential copy-number alterations (CNA), mutations, DNA methylation, and miRNA expression between patients that responded to standard treatment and those who did not or recurred prematurely. We correlated these significant parameters with gene expression to create a signature of 422 genes associated with chemoresponse. A consensus clustering of this signature identified two differentiated clusters with unique molecular patterns: cluster 1 was signi ficant for cellular signaling and immune response (mainly cell-mediated); and cluster 2 was significant for pathways involving DNA-damage repair and replication, cell cycle, and apoptosis. Validation through consensus clustering was performed in five independent OVCA gene-expression experiments. Genes were located in the same cluster with consistent agreement in all five studies (κ coefficient ≥ 0.6 in 4). Integrating high-throughput biologic data have created a robust molecular signature that predicts chemoresponse in OVCA.",
author = "{Gonzalez Bosquet}, Jesus and Marchion, {Douglas C.} and HyeSook Chon and Lancaster, {Johnathan M.} and Stephen Chanock",
year = "2014",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-14-0186",
language = "English (US)",
volume = "74",
pages = "3902--3912",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data

AU - Gonzalez Bosquet, Jesus

AU - Marchion, Douglas C.

AU - Chon, HyeSook

AU - Lancaster, Johnathan M.

AU - Chanock, Stephen

PY - 2014/7/15

Y1 - 2014/7/15

N2 - A third of patients with epithelial ovarian cancer (OVCA) will not respond to standard treatment. The determination of a robust signature that predicts chemoresponse could lead to the identification of molecular markers for response as well as possible clinical implementation in the future to identify patients at risk of failing therapy. This pilot study was designed to identify biologic processes affecting candidate pathways associated with chemoresponse and to create a robust gene signature for follow-up studies. After identifying common pathways associated with chemoresponse in serous OVCA in three independent gene-expression experiments, we assessed the biologic processes associated with them using The Cancer Genome Atlas (TCGA) dataset for serous OVCA. We identi fied differential copy-number alterations (CNA), mutations, DNA methylation, and miRNA expression between patients that responded to standard treatment and those who did not or recurred prematurely. We correlated these significant parameters with gene expression to create a signature of 422 genes associated with chemoresponse. A consensus clustering of this signature identified two differentiated clusters with unique molecular patterns: cluster 1 was signi ficant for cellular signaling and immune response (mainly cell-mediated); and cluster 2 was significant for pathways involving DNA-damage repair and replication, cell cycle, and apoptosis. Validation through consensus clustering was performed in five independent OVCA gene-expression experiments. Genes were located in the same cluster with consistent agreement in all five studies (κ coefficient ≥ 0.6 in 4). Integrating high-throughput biologic data have created a robust molecular signature that predicts chemoresponse in OVCA.

AB - A third of patients with epithelial ovarian cancer (OVCA) will not respond to standard treatment. The determination of a robust signature that predicts chemoresponse could lead to the identification of molecular markers for response as well as possible clinical implementation in the future to identify patients at risk of failing therapy. This pilot study was designed to identify biologic processes affecting candidate pathways associated with chemoresponse and to create a robust gene signature for follow-up studies. After identifying common pathways associated with chemoresponse in serous OVCA in three independent gene-expression experiments, we assessed the biologic processes associated with them using The Cancer Genome Atlas (TCGA) dataset for serous OVCA. We identi fied differential copy-number alterations (CNA), mutations, DNA methylation, and miRNA expression between patients that responded to standard treatment and those who did not or recurred prematurely. We correlated these significant parameters with gene expression to create a signature of 422 genes associated with chemoresponse. A consensus clustering of this signature identified two differentiated clusters with unique molecular patterns: cluster 1 was signi ficant for cellular signaling and immune response (mainly cell-mediated); and cluster 2 was significant for pathways involving DNA-damage repair and replication, cell cycle, and apoptosis. Validation through consensus clustering was performed in five independent OVCA gene-expression experiments. Genes were located in the same cluster with consistent agreement in all five studies (κ coefficient ≥ 0.6 in 4). Integrating high-throughput biologic data have created a robust molecular signature that predicts chemoresponse in OVCA.

UR - http://www.scopus.com/inward/record.url?scp=84904246388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904246388&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0186

DO - 10.1158/0008-5472.CAN-14-0186

M3 - Article

C2 - 24848511

AN - SCOPUS:84904246388

VL - 74

SP - 3902

EP - 3912

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -